Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ULK1 | O75385 | 1/20 | 0.39 |
| ▸ | ULK2 | Q8IYT8 | 1/20 | 0.39 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.35 |
| ▸ | HTT | P42858 | 1/20 | 0.35 |
| ▸ | PIK3R1 | P27986 | 1/20 | 0.34 |
| ▸ | PIK3CA | P42336 | 1/20 | 0.34 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.33 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.33 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.33 |
| ▸ | RAB9A | P51151 | 2/20 | 0.33 |
| ▸ | NPC1 | O15118 | 1/20 | 0.33 |
| ▸ | LMNA | P02545 | 1/20 | 0.33 |
| ▸ | POLB | P06746 | 1/20 | 0.33 |
| ▸ | MAPT | P10636 | 1/20 | 0.33 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.33 |
| ▸ | GFER | P55789 | 1/20 | 0.33 |
| ▸ | ITGB2 | P05107 | 2/20 | 0.33 |
| ▸ | ICAM1 | P05362 | 2/20 | 0.33 |
| ▸ | ITGAL | P20701 | 2/20 | 0.33 |
| ▸ | ACP1 | P24666 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL22648322 | 0.86 | IRAK4 (0.35) | ULK1ULK2SMN1; SMN2HTTPIK3R1 | |
| SCHEMBL22634742 | 0.86 | SMN1; SMN2 (0.43) | ULK1ULK2SMN1; SMN2HTTKDM4E | |
| SCHEMBL22648420 | 0.85 | ULK1 (0.52) | ULK1ULK2SMN1; SMN2HTTPIK3R1 | |
| SCHEMBL25918880 | 0.85 | ALDH1A1 (0.44) | ULK1ULK2SMN1; SMN2HTTKDM4E | |
| SCHEMBL25008387 | 0.82 | ULK1 (0.44) | ULK1ULK2SMN1; SMN2HTTKDM4E | |
| SCHEMBL22634468 | 0.78 | ULK1 (0.53) | ULK1ULK2 | |
| SCHEMBL29449182 | 0.78 | ULK1 (0.53) | ULK1ULK2 | |
| SCHEMBL29490425 | 0.77 | ULK1 (0.39) | ULK1ULK2SMN1; SMN2HTTPIK3CA | |
| SCHEMBL29490639 | 0.77 | ULK1 (0.44) | ULK1ULK2SMN1; SMN2HTTALDH1A1 | |
| SCHEMBL29490537 | 0.76 | ULK1 (0.44) | ULK1ULK2SMN1; SMN2HTTITGB2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3966207-B1 | PHENYLAMINOPYRIMIDINE AMIDE AUTOPHAGY INHIBITORS AND METHODS OF USE THEREOF | DECIPHERA PHARMACEUTICALS LLC (US) | 2023-11-01 | — | — | EP | disclosed |
| EP-3966206-B1 | HETEROARYLAMINOPYRIMIDINE AMIDE AUTOPHAGY INHIBITORS AND METHODS OF USE THEREOF | DECIPHERA PHARMACEUTICALS LLC (US) | 2023-08-09 | — | — | EP | disclosed |
| US-20230047915-A1 | HETEROARYLAMINOPYRIMIDINE AMIDE AUTOPHAGY INHIBITORS AND METHODS OF USE THEREOF | DECIPHERA PHARMACEUTICALS, LLC | 2023-02-16 | — | — | US | disclosed |
| US-11530206-B2 | Phenylaminopyrimidine amide autophagy inhibitors and methods of use thereof | DECIPHERA PHARMACEUTICALS, LLC (US) | 2022-12-20 | — | — | US | disclosed |
| US-11518758-B2 | Heteroarylaminopyrimidine amide autophagy inhibitors and methods of use thereof | DECIPHERA PHARMACEUTICALS, LLC (US) | 2022-12-06 | — | — | US | disclosed |
| WO-2020231806-A1 | PHENYLAMINOPYRIMIDINE AMIDE AUTOPHAGY INHIBITORS AND METHODS OF USE THEREOF | DECIPHERA PHARMACEUTICALS, LLC (US) | 2020-11-19 | — | — | WO | disclosed |
| WO-2020231808-A1 | HETEROARYLAMINOPYRIMIDINE AMIDE AUTOPHAGY INHIBITORS AND METHODS OF USE THEREOF | DECIPHERA PHARMACEUTICALS, LLC (US) | 2020-11-19 | — | — | WO | disclosed |
| US-20200354346-A1 | HETEROARYLAMINOPYRIMIDINE AMIDE AUTOPHAGY INHIBITORS AND METHODS OF USE THEREOF | DECIPHERA PHARMACEUTICALS, LLC | 2020-11-12 | — | — | US | disclosed |
| US-20200354352-A1 | PHENYLAMINOPYRIMIDINE AMIDE AUTOPHAGY INHIBITORS AND METHODS OF USE THEREOF | DECIPHERA PHARMACEUTICALS, LLC | 2020-11-12 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230047915-A1 | HETEROARYLAMINOPYRIMIDINE AMIDE AUTOPHAGY INHIBITORS AND METHODS OF USE THEREOF | BECN1, SQSTM1, ATG7 | ULK1 4/4885ULK2 8/4885SMN1; SMN2 3749/4885 |
| US-11530206-B2 | Phenylaminopyrimidine amide autophagy inhibitors and methods of use thereof | BECN1, SQSTM1, ATG7 | ULK1 4/4885ULK2 9/4885SMN1; SMN2 3477/4885 |
| US-20200354352-A1 | PHENYLAMINOPYRIMIDINE AMIDE AUTOPHAGY INHIBITORS AND METHODS OF USE THEREOF | BECN1, SQSTM1, ATG7 | ULK1 4/4885ULK2 9/4885SMN1; SMN2 3477/4885 |
| US-20200354346-A1 | HETEROARYLAMINOPYRIMIDINE AMIDE AUTOPHAGY INHIBITORS AND METHODS OF USE THEREOF | BECN1, SQSTM1, ATG7 | ULK1 4/4885ULK2 8/4885SMN1; SMN2 3749/4885 |
| US-11518758-B2 | Heteroarylaminopyrimidine amide autophagy inhibitors and methods of use thereof | BECN1, SQSTM1, ATG7 | ULK1 4/4885ULK2 8/4885SMN1; SMN2 3749/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.